Navigation Links
Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
Date:6/22/2011

SAN DIEGO, June 22, 2011 /PRNewswire/ -- Ambrx Inc. today announced that Ho Cho, Ph.D., the company's Chief Technology Officer, will present preclinical data from the company's antibody drug conjugate (ADC) programs at five upcoming scientific conferences. The presentations will include data obtained from recent xenograft studies comparing Ambrx ADCs with those created using other technologies.

"Ambrx technology has been clinically validated as safe and efficacious for creating PEGylated proteins, and we have recently focused our efforts on creating site-specific conjugates of antibodies with best-in-class potential," Dr. Cho said. "Preclinical data obtained from partnered and unpartnered programs show us that the application of our technology to creating ADCs has tremendous potential. We look forward to presenting this promising data to the scientific community over the coming months."

At the IBC Life Sciences' Next Generation Protein Therapeutics Summit in San Francisco, Dr. Cho will deliver a presentation titled "Synthetic Biology Applied to Biotherapeutics" at 1:30 p.m. PDT on June 22, 2011.

At the American Chemical Society's 242nd National Meeting in Denver, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry with an Expanded Genetic Code" at 9 a.m. MDT on August 29, 2011.

At the Cambridge Healthtech Institute's PEGs Europe conference in Hannover, Germany, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry Applied to Antibody Drug Conjugates" at 3:05 p.m. CEST on October 11, 2011.

At the World Antibody Drug Conjugate Summit in San Francisco, Dr. Cho will deliver a presentation titled "Optimized Antibody Drug Conjugates with an Expanded Genetic Code" at 10 a.m. PDT on October 27, 2011.

Dr. Cho will also deliver a presentation at the IBC Life Sciences' Empowered Antibody Therapies Conference, held August 1-3, 2011, in San Francisco.

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using its broad biologics platform to create best-in-class therapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx is developing several product candidates in collaboration with Eli Lilly and Company, including a Phase 3 compound expected to be launched commercially in 2013. The company has validated its biologics platform through additional partnerships with Pfizer and Merck & Co Inc.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contacts:

David Schull or Ian Stone
Russo Partners
T: (212) 845-4271
T: (619) 528-2220
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Ambrx Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology
2. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
3. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
4. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
5. Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference
6. Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
7. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
8. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
9. Simulated Environment Concepts to Present at National Eagles and Angels Association New York Meeting
10. Radiation Therapy Services Holdings, Inc. to Present at the Wells Fargo Securities 2011 Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):